Myocardial 11C-diacylglycerol accumulation and left ventricular remodeling in patients after myocardial infarction.

Hiroki Otani, Yutaka Kagaya, Yoshio Imahori, Satoshi Yasuda, Ryo Fujii, Masanobu Chida, Shigeto Namiuchi, Morihiko Takeda, Masahito Sakuma, Jun Watanabe, Tatsuo Ido, Hiroshi Nonogi, Kunio ShiratoPubMed 2005

TL;DR

This study introduces a novel PET imaging technique using the radiotracer ¹¹C-diacylglycerol (¹¹C-DAG) to visualize and quantify myocardial phosphoinositide cycle activity in patients recovering from myocardial infarction (MI). The findings demonstrate that increased ¹¹C-DAG accumulation in the non-infarcted myocardium is directly correlated with adverse left ventricular (LV) remodeling, including enlargement and systolic dysfunction, offering a promising new tool for assessing and managing post-MI patients.

What Problem Does This Paper Address?

Left ventricular (LV) remodeling after a myocardial infarction (MI) is a critical, often maladaptive, process that significantly increases the risk of heart failure and death. Understanding and quantifying this remodeling process is crucial for effective patient management and treatment. The phosphoinositide cycle, a key intracellular signaling pathway, is implicated in LV remodeling. However, a non-invasive method to assess the activity of this pathway in the human heart, particularly in the context of post-MI remodeling, has been lacking. This paper aims to bridge this gap by investigating whether ¹¹C-DAG, a radiotracer that visualizes the phosphoinositide cycle, can serve as a marker for LV remodeling in patients who have experienced an MI.

Methods

The researchers employed Positron Emission Tomography (PET) to image myocardial ¹¹C-DAG accumulation. They synthesized ¹¹C-DAG, a ¹¹C-labeled diacylglycerol, and administered it intravenously to both post-MI patients and healthy volunteers. PET scans were performed to capture the distribution of the tracer. Regions of interest (ROIs) were placed on the non-infarcted myocardium and the left atrial (LA) chamber. The ratio of ¹¹C-DAG accumulation in the myocardium to that in the LA chamber (myocardium-to-LA chamber ratio) was calculated. This ratio was then correlated with various clinical parameters indicative of LV remodeling, including LV end-diastolic volume index (LVEDVI), LV ejection fraction (LVEF), and plasma brain natriuretic peptide (BNP) levels, which serve as a marker of cardiac strain and neurohumoral activation. Echocardiography was also used to assess LV dimensions and wall thickness.

Datasets

The study utilized data from two groups:

  • Post-MI Patients: 13 patients who had experienced anteroseptal Q-wave MI, with clinical characteristics detailed in Table 1.
  • Healthy Volunteers: 4 individuals serving as a control group.

No new benchmarks were introduced; the study focused on correlating PET findings with established clinical and echocardiographic measures of cardiac health and remodeling.

Key Insights and Ideas

  • ¹¹C-DAG as a Marker for Phosphoinositide Activity: The study builds upon previous animal research, confirming that ¹¹C-DAG can be metabolized into intermediates of the phosphoinositide cycle, making it a suitable tracer for visualizing this pathway in vivo.
  • Increased Phosphoinositide Activity in Post-MI Hearts: A key finding is that post-MI patients exhibit significantly higher myocardial ¹¹C-DAG accumulation compared to healthy volunteers. This suggests an activated phosphoinositide cycle in the remote, viable myocardium of these patients.
  • Correlation with Adverse Remodeling: The most significant insight is the strong correlation between elevated myocardial ¹¹C-DAG accumulation and indicators of adverse LV remodeling. This includes a direct correlation with LV enlargement (higher LVEDVI) and elevated BNP levels, and an inverse correlation with LV systolic function (lower LVEF).
  • Potential for Early Detection: This imaging strategy offers the potential to identify patients at higher risk for progressive LV remodeling and heart failure, even in the chronic phase after MI, by visualizing an underlying molecular signaling abnormality.

Key Results

  • The myocardium-to-LA chamber ratio of ¹¹C-DAG accumulation was significantly higher in post-MI patients (1.73 ± 0.35) compared to healthy volunteers (1.25 ± 0.13) (P < 0.05).
  • In post-MI patients, the myocardium-to-LA chamber ratio of ¹¹C-DAG showed a strong positive correlation with LV end-diastolic volume index (r = 0.79, P < 0.01) and plasma BNP concentration (r = 0.85, P < 0.001).
  • Conversely, the ratio showed a significant negative correlation with LV ejection fraction (r = -0.69, P < 0.01).
  • The study noted that while some patients were on ACE inhibitors or ARBs, the ¹¹C-DAG accumulation was not significantly different between those treated with and without these medications, suggesting that the observed signaling might persist or be influenced by other factors.

Limitations and Future Work

The authors acknowledge several limitations:

  • Partial-Volume Effect: The study did not correct for the partial-volume effect, which could potentially influence the measured ¹¹C-DAG counts, especially in areas with altered wall thickness. However, they argue that this effect is unlikely to fully explain the observed differences, as wall thickness was not significantly increased in post-MI patients compared to controls, and the ¹¹C-DAG ratio did not correlate with wall thickness.
  • Variability in MI Onset and Extent: The time elapsed since MI and the initial extent of infarction varied among patients, which could influence remodeling. However, the time after MI was not significantly correlated with the ¹¹C-DAG ratio.
  • Inability to Assess Metabolic Fate: Myocardial biopsy was not performed, preventing direct assessment of the metabolic fate of ¹¹C-DAG in human myocardium. Previous animal studies indicated metabolism to phosphoinositide intermediates, but other pathways were also observed.

Future work suggested includes:

  • Larger Population Studies: Further studies with larger cohorts are needed to solidify the clinical significance of ¹¹C-DAG PET in post-MI patients.
  • Therapeutic Interventions: Investigating the impact of increasing medication doses (e.g., ACE inhibitors, ARBs) or adding new drugs on ¹¹C-DAG accumulation could provide insights into treatment optimization.
  • Broader Signaling Pathways: Exploring the role of other signaling pathways (e.g., endothelin-1, α₁-adrenergic receptors) that influence the phosphoinositide cycle is warranted.
  • Clarifying Baseline Activity: Further research is needed to understand the implications of the mild ¹¹C-DAG accumulation observed in healthy volunteers.

Summary updated

Abstract

These findings suggest that the myocardial 11C-DAG accumulation assessed by PET is relevant to LV enlargement, LV systolic dysfunction, and humoral activation in post-MI patients. This new imaging strategy based on intracellular signaling may contribute to the assessment and treatment of post-MI patients.
BibTeX
@inproceedings{otani2005myocardial,
  author = {Hiroki Otani and Yutaka Kagaya and Yoshio Imahori and Satoshi Yasuda and Ryo Fujii and Masanobu Chida and Shigeto Namiuchi and Morihiko Takeda and Masahito Sakuma and Jun Watanabe and Tatsuo Ido and Hiroshi Nonogi and Kunio Shirato},
  title = {{Myocardial 11C-diacylglycerol accumulation and left ventricular remodeling in patients after myocardial infarction.}},
  booktitle = {PubMed},
  year = {2005},
}
Figure